49 results about "Asthenozoospermia" patented technology

The invention discloses uses of lysine with + 42.01108 mass shift occurring at a 531 site of ATP5A1 protein as a biomarker in preparation of an oligo / asthenozoospermia diagnostic reagent. The oligo / asthenozoospermia can be diagnosed by the test frequency of + 42.01108 mass shift occurring at a 531 site of ATP5A1 protein, and a new diagnosis and treatment target point is provided for the oligo / asthenozoospermia.

The invention discloses a medicine for treating male oligospermia and asthenozoospermia and improving sperm quality. The medicine for treating male oligospermia and asthenozoospermia and improving sperm quality takes L-carnitine, maca, corduceps militaris, zinc-rich selenium-rich whole egg powder, vitamin C, citric acid, zizyphus jujube, deer blood, folic acid, taurine, fructose and coenzyme Q10 as active compositions, and is prepared according to a certain weight ratio. The medicine aims at the disadvantages of conventional spermatogenic medicines, and is reasonable in formula. By properly combining multiple bulk drugs and utilizing the mutual synergic effect of the bulk drugs, the treatment effect is improved, the medicine adapts to treatment requirements of complex disease conditions, adverse reaction is reduced, and the medicine is durable in treatment effect, fast in absorption, rapid in effectiveness, strong in effect, free of stimulation, safe, reliable and simple for administration, is capable of effectively promoting generation of sperms, improving the survival rate of sperms, and is an effective medicine for treating oligospermia, asthenozoospermia and sperm quality badness caused by various reasons. The total effective rate of the medicine reaches 95.6% based on 5730 examples treated by using the medicine.

After sampling semen from healthy males and from patients whose chief complaint was infertility, the semen volume, sperm concentration, sperm motility rate, and sperm survival rate in each of the specimens were measured, sperm-bound SPMI was detected using an anti-SPMI antibody, and the amount and rate of SPMI binding were calculated. As a result, only patient specimens were found in the specimen group with amount and rate of SPMI binding above a certain level. Diagnosis of asthenozoospermia can be made by determining the amount and rate of SPMI binding.

The invention discloses a Chinese medicine composition for curing oligospermia and asthenozoospermia and a preparation method of Chinese medicine composition and relates to the technical field of Chinese herbal medicines. The Chinese medicine composition comprises, by weight, 10-15 grams of Chinese wolfberry fruits, 3-8 grams of rehmannia glutinosa, 10-20 grams of Chinese dodder seeds, 5-15 grams of dogwood, 5-15 grams of raspberry, 5-15 grams of cistanche, 10-20 grams of polygonum multiflorum, 10-20 grams of red-rooted saliva roots, 10-20 grams of herba epimedii, 5-15 grams of pericarpium citri reticulatae, 5-15 grams of codonopsis pilosula, 5-15 grams of rhizoma atractylodis macrocephalae, 3-10 grams of liquorice, 5-15 grams of rhizoma polygonati, 5-15 grams of angelic sinensis and 5-15 grams of poria cocos. The Chinese medicine composition can effectively promote spermatogenesis, increase survival rate of sperms and sperm activity, is used for curing the oligospermia and the asthenozoospermia resulted from pathogenic reasons, is particularly suitable for idiopathic oligospermia or asthenospermia, and simple, safe, convenient and effective to take.

The invention discloses a traditional Chinese medicine for treating male infertility. The traditional Chinese medicine comprises the following components in parts by weight: 8-10 parts of radix rehmanniae, 30-35 parts of fructus lycii, 3-5 parts of panax notoginseng, 10-12 parts of angelica sinensis, 10-12 parts of rhizoma polygonati odorati, 10-12 parts of rhizoma polygonati, 8-10 parts of flatstem milkvetch seed, 10-12 parts of fructus mori albae, 10-12 parts of poria, 8-10 parts of nightblooming cereus, 10-12 parts of cortex phellodendri, 10-12 parts of polycarpaea corymbosa, 10-12 parts of aster striatus, 10-12 parts of semen cuscutae, 5-8 parts of herba epimedii, 8-10 parts of herba cistanche, 8-10 parts of semen plantaginis, 3-5 parts of ginseng and 5-8 parts of panax quinquefolium. The traditional Chinese medicine has good effect on infertility caused by dysspermia, namely non-liquefied semen and patients with asthenozoospermia, and has no any toxic or side effect.

The invention relates to a biomarker for assisting the diagnosis of sudden asthenozoospermia and application thereof. The biomarker is characterized in that a CpG methylation locus is in a peripheralblood leucocyte DAZ3 gene promoter area. A kit comprises quantitative PCR primers for detecting the methylation locus. The biomarker, a method and the kit have the advantages that peripheral blood leucocyte can be easily obtained, other tissue is not needed, and noninvasive examination is achieved; peripheral blood leucocyte DAZ3 gene promoter area methylation reflects the overall pathological andphysiological conditions of a human body, and diagnosis accuracy can be increased by using the CpG methylation locus as the biomarker for assisting the diagnosis of sudden asthenozoospermia; the kitsimplifies a quantitative PCR primer library, production cost and production time are reduced, targeting performance and practicality are increased, and detection sensitivity and specificity are increased; the biomarker, the method and the kit can be used for assisting the diagnosis of sudden asthenozoospermia.

The invention relates to a medicine composition for treating male infertility and particularly relates to a medicine composition for treating male oligospermia / asthenozoospermia infertility. The traditional Chinese medicine composition contains the following ingredients: (a) radix rehmanniae praeparata, (b) rhizoma polygonati preparata, (c) cistanche deserticola and (d) bitter melon slices.

The invention provides a traditional Chinese medicine composition and its preparation method and application, and relates to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition for treating male infertility provided by the invention includes Rehmannia glutinosa, Cuscuta, Astragalus, Epimedium, Salvia miltiorrhiza, Achyranthes achyranthes, leech, Milletah, and Passepartout. The traditional Chinese medicine composition provided by the invention can significantly improve sperm motility, activity rate and sperm linear motion speed, and its clinical curative effect is better than that of conventional Chinese patent medicines. It provides an effective prescription for the clinical treatment of idiopathic asthenozoospermia and male infertility. The drug has a wide range of drug sources, low price, no toxic side effects, reasonable prescription, good curative effect, quick effect, economic benefits, not easy to relapse and no damage to the human body, etc., and is worthy of popularization and application. The preparation method of the traditional Chinese medicine composition provided by the present invention uses the composition of the present invention as a raw material, and adopts a physical method of decoction to extract and utilize the active ingredients in the composition, and has the advantages of simple preparation method and quick drug effect.

The invention relates to a prescription for treating As-permia and Oligosperm, which is characterized by comprising the following components in part by weight: 1 to 30 parts of astragalus root, 1 to 30 parts of Paeonia veitchii, 1 to 30 parts of angelica sinensis, 1 to 30 parts of root of red-rooted salvia, 1 to 30 parts of mulberry, 1 to 30 parts of fructus ligustri lucidi, 1 to 30 parts of Chinese magnoliavine fruit, 1 to 30 parts of plantain seed, 1 to 30 parts of Cuscuta chinensis and 1 to 30 parts of herba epimedii. The above traditional Chinese composition can be processed into medicinal broth, pills and powder. The prescription has the advantages that compared with the similar product, when the prescription is used for improving the asthenozoospermia and Oligospermia, the effect is fast and the treatment period is shortened, thereby favoring the rehabilitation of the patients.

The invention relates to an asthenozoospermia treatment device. The asthenozoospermia treatment device includes an ultrasonic wave generating unit (1), an impact wave generating unit (2) and therapeutic probes (3, 3'); the ultrasonic wave generating unit (1) and the impact wave generating unit (2) are operatively coupled to the therapeutic probes (3, 3'); and therapeutic ultrasound waves and / or therapeutic impact waves can be selectively delivered to an asthenozoospermia treatment part by the therapeutic probes (3, 3'). The invention adopts an in-vitro treatment mode for using the therapeuticprobes to selectively emit the therapeutic ultrasonic waves and / or the therapeutic impact waves to the asthenozoospermia treatment part of a human body, can utilize beneficial biological effects and physical effects brought by the ultrasonic waves and the shock waves to improve the number of sperms moving forward in the semen and the forward movement ability of the sperms, can improve the overallvitality of the sperms so as to treat the male infertility due to the asthenozoospermia, is easy to use, and has obvious therapeutic effects.

The invention relates to a traditional Chinese medicine preparation for treating asthenozoospermia, which comprises the Chinese medicinal herbs in parts by weight: 30 parts of radix paeoniae alba, 20 parts of raspberry, 10 parts of liquorice, 5 parts of centipede, 20 parts of Chinese angelica, 10 parts of corydalis tuber, 100 parts of seed of cowherb, 10 parts of fructus aurantii, 10 parts of fushen and 10 parts of polygala root. Animal experiments and clinical tests prove that the traditional Chinese medicine preparation can improve the sperm motility of men, thereby improving the fertilization rate.

The invention relates to an application of a methylation level of a human CDR1 gene promoter region in preparation of a detection agent for detecting sperm motility. The human CDR1 gene promoter region is located in a region corresponding to the 139866223 to 139868923 sites of a human X chromosome. The analysis and research are carried out on the basis of a whole genome methylation sequencing result, the verification shows that the methylation level of the human CDR1 gene promoter region has significant difference between an asthenozoospermia patient and a healthy person, and the human CDR1 gene promoter region can be used as a molecular marker to diagnose whether a subject suffers from asthenozoospermia or not. When the methylation rate of the region is higher than 0.63, the probability that the subject suffers from asthenozoospermia is high. The molecular marker can provide auxiliary evaluation information for diagnosis of asthenozoospermia, and is combined with other diagnosis indexes to identify whether the subject suffers from asthenozoospermia or not.

The invention discloses a yishenling granule and a preparation method thereof. The yishenling granule is characterized by being prepared through the following steps: taking 280g of inula flower, 38g of resin of sweetgum, 80 of siegesbeckia herb, 200g of Chinese wolfberry, 300g of glossy privet fruit, 20g of processed aconite root, 300g of gorgon fruit, 100g of plantain seed, 200g of malaytea scurfpea fruit, 200g of raspberry, 50g of the fruit of Chinese magnoliavine, and 200g of mulberry, grinding the raw materials into coarse powder, putting the coarse powder into a cyclic ultrasonic extractor, adding water, germanium powder and tween 60, performing ultrasonic extraction and jet spray-drying to obtain nano extract powder, and then adding lactose and dextrin to obtain the yishenling granules. The yishenling granules are used for treating impotence, premature ejaculation, spermatorrhea or asthenozoospermia caused by kidney qi deficiency and yang-qi deficiency; the curative effect of the yishenling granules is remarkably superior to that of the yishenling granules in the market; a good effect is achieved.

The invention provides a drug for treatment of asthenozoospermia, and the drug comprises the following materials: by weight, 8-15 parts of curculigo orchioides, 6-12 parts of herba epimedii, 10-15 parts of semen cuscutae, 8-12 parts of Chinese yam, 12-18 parts of hippocampus, 8-12 parts of loranthus parasiticus, 8-15 parts of prepared rehmannia root, 7-11 parts of cornus officinalis, 8-12 parts of rhizoma alismatis, 10-18 parts of poria cocos and 8-12 parts of licorice. The drug for treatment of asthenozoospermia has the advantages and positive effects of good curative effect, small side effect and low treatment cost.

The invention discloses a moringa oleifera preparation for treating asthenozoospermia and oligospermia. The moringa oleifera preparation is mainly prepared from the following raw materials in parts by weight: 1 to 40 parts of moringa oleifera leaves, 1 to 20 parts of mulberry fruits, 1 to 20 parts of Chinese wolfberry fruits, 1 to 20 parts of oyster shells and 1 to 20 parts of oyster meat or oyster meat extracts. The invention also provides a preparation method of the moringa oleifera preparation for treating asthenozoospermia and oligospermia, and application of the moringa oleifera preparation for treating asthenozoospermia and oligospermia. The moringa oleifera preparation provided by the invention has the efficacies of invigorating the kidney, strengthening Yang, nourishing Yin, replenishing essence, replenishing qi, nourishing blood, removing heat from the liver, smoothing the gall bladder, removing dampness, promoting blood circulation, moistening dryness, relieving diarrhea and the like; the moringa oleifera preparation can be used for treating asthenozoospermia and oligospermia of male adults, can also be used for treating maldevelopment and developmental retardation of teenagers and spleen and kidney Yang deficiency type iron deficiency anemia, and can also be used by ladies for beauty treatment, freckle removal and the like; the effect is obvious; no hormone is contained; and no untoward effect and no toxic and side effects exist.

The invention discloses a method for improving sperm function of asthenozoospermia by using exosomes, and belongs to the technical field of medicine. The method comprises the following three steps: separation of normal human seminal plasma exosomes, screening and pretreatment of asthenospermia sperms, and intervention of the exosomes on the asthenospermia sperms. The seminal plasma exosomes from the human body are used for intervening sperms in vitro, functions of the sperm motility and the like are improved, so that the asthenozoospermia is intervened and treated through simple non-invasive means such as artificial fertilization, and the fertility outcome of a patient is improved.

The invention provides medicine for treating male infertility and a preparation method thereof. Male infertility refers to infertility caused by male elements, aetiological agents of the disease are complex, and plenty of diseases or elements can cause male infertility. Clinically, male infertility is categorized into sexual dysfunction and normal sexual function, and the normal sexual function condition can be further divided into such symptoms as azoospermatism, oligospermia, asthenozoospermia and asthenospermia. The medicine is prepared by combining cynomorium coccineum, corn cervi pantotrichum, yam rhizomes, human placenta, white atractylodes rhizome, vigna umbellata, radix angelica sinensis, morinda officinalis, rush, epimedium herbs, rhizoma cibotii, fructus psoraleae, fructus alpiniae oxyphyllae, flatstem milkvetch seeds, exocarpium benincasae, actinolite, polygonum multiflorum, adenophora roots, dendrobe, semen allii tuberosi, sealwort, Chinese wolfberry fruits, mulberries, glossy privet fruits, black sesame, seal penes, prepared rehmannia roots, cistanche, gekko, radix paeoniae alba, lily, radix ophiopogonis and radix polygonati officinalis. All drugs are combined, so that all the drugs achieve a synergistic effect in efficacy, and thereby male infertility can be effectively treated.

The invention discloses traditional Chinese medicine powder for treating dyszoospermia. The traditional Chinese medicine powder for treating dyszoospermia is prepared from, by weight, 10-14 parts of Fructus Mori, 10-14 parts of Herba Epimedii, 10-14 parts of Pericaypium Citri Grandis, 8-12 parts of Rhizoma Polygonati, 7-11 parts of Fructus Lycii, 7-11 parts of Radix et Rhizoma Rhodiolae, 3-5 parts of ginseng and 3-5 parts of Flos Carthami. The traditional Chinese medicine powder is capable of promoting spermatogenesis and protecting injured testicles, can be used for treating azoospermia, asthenozoospermia and oligospermia and is remarkable in curative effect and free of side effects.

The invention provides a traditional Chinese medicine preparation for treating oligospermia / asthenozoospermia. The traditional Chinese medicine preparation is characterized by being prepared from the following active pharmaceutical ingredients by weight: 11-13g of tendons of beef, 14-16g of goat or sheep bones, 9-11g of radix astragali, 9-11g of seed of common jujube, 14-16g of tuber fleeceflower root, 14-16g of radix notoginseng, 5-7g of liquorice root, 14-16g of epimedium herb, 9-11g of common macrocarpium fruit, 9-11g of tangerine peel, 9-11g of fried largehead atractylodes rhizome, 5-7g of deer sinew, 9-11g of Jiuxiang bug, 4-6g of sunset abelmoschus, 9-11g of coix seed, 4-6g of Szechuan lovage rhizome, 9-11g of ginkgo leaf, 4-6g of deerhorn glue, 9-11g of lucid ganoderma, 4-6g of glossy privet fruit, 4-6g of Indian buead, 9-11g of sunflower seed, 4-6g of lily, 9-11g of Chinese angelica and 9-11g of tuber onion seed. The traditional Chinese medicine preparation can conduce to effectively promoting spermatogenesis, increasing the sperm survival rate and reinforcing the sperm motility, is used for treating oligospermia and asthenospermia caused by various reasons, especially idiopathic oligospermia or idiopathic asthenospermia, is simple to take and is safe, convenient and effective.

The invention discloses application of serine, which is used as a biological marker and has +79.96685 mass shift at a 208 site of AKAP3 (A-kinase Anchor Protein 3), to preparation of a diagnostic reagent or a treatment medicine of severe oligoasthenospermia. According to the application disclosed by the invention, the severe oligoasthenospermi can be diagnosed through testing frequency of the +79.96685 mass shift occurring at the 208 site of the AKAP3, and new diagnosis and new treatment target spots are provided for the severe oligoasthenospermia.

The invention relates to male function foods and a preparation method thereof. The male function foods comprises the following components in percentage by weight: 50-70 percent of quinoa, 25-45 percent of wheat and 5-10 percent of velvet antler extract. The preparation method of the male function foods comprises the following steps of step 1, performing high-temperature and high-pressure treatmenton the quinoa, the wheat and the velvet antler extract under 4 conditions with standard atmospheric pressure and the temperature being 120 DEG C for standby; and step 2, weighing the quinoa, the wheat and the velvet antler extract which are treated with step 1 according to the weight percentage, and performing uniform mixing to prepare the function foods. The male function foods provided by the invention can remarkably increases the sperm amount and the sperm motility of patients with oligospermia and asthenozoospermia and does not have side effect and adverse reaction as various components are all edible components. Clinical effect results show that in 60 patients, 28 patients are cured, 18 patients are effectively treated, 4 patients are effective, 10 patients are invalid, and the totaleffective rate is 83.33 percent.

The invention relates to application of methylation level of a human PKP3 gene promoter region in preparing a detection agent for preparing sperm activity. The human PKP3 gene promoter region is a region corresponding to space from 392017th to 394717th of a human 11th chromosome. Analysis, research and verification on the basis of whole genome methylation sequencing results finds that the methylation level of the human PKP3 gene promoter region can serve as a molecular marker to detect the sperm activity, and when all methylation sites of the region are not completely methylated, it can be thought that activity of corresponding sperms is weak. The molecular marker can provide assistant evaluation information for diagnosis of asthenozoospermia and selection of sperms before artificial fertilization.

The invention provides a traditional Chinese medicine composition for treating asthenozoospermia. The traditional Chinese medicine composition is characterized by being prepared through the following traditional Chinese medicine materials in parts by weight: 15-30 parts of radix trichosanthis, 5-15 parts of placenta hominis, 10-25 parts of rhizoma polygonati, 5-20 parts of caulis polygoni multiflori, 10-35 parts of radix rehmanniae preparata, 5-15 parts of radix morindae officinalis, 5-20 parts of herba epimedii, 5-15 parts of cortex phellodendri, 5-15 parts of sargentodoxa stem, 5-20 parts of cortex eucommiae, 5-15 parts of rhizoma sparganii, and 5-15 parts of rhizoma curcumae. According to the theory of traditional Chinese medicine and aiming at the pathogenesis of oligozoospermia and asthenozoospermia, the traditional Chinese medicine composition is prepared referring to the modern pharmacological research, the dialectical compound and compatibility can be conducted by adopting a therapy of nourishing liver and kidney and producing sperm and tonifying marrows, the spermatogenesis can be effectively promoted, the sperm activity rate can be improved, the motility of sperm can be enhanced, the traditional Chinese medicine composition can treat oligozoospermia and asthenozoospermia caused due to various reasons, and is safe, convenient, good in curative effect, high in cure rate, and free from toxic and side effects.

The invention discloses a microsperm cryopreservation method, aiming to provide a microsperm with small volume, closed space, easy operation and high sperm activity (including a single sperm, such as testicular puncture sperm, epididymal puncture sperm, severe The cryopreservation carrier and cryopreservation method of the sperm of patients with oligospermia and asthenospermia, etc.) When the sperm is recovered, take out the cryopreservation tube from the liquid nitrogen tank, take out the cryopreservation carrier from the cryopreservation tube with a straw, and quickly add it to the sperm culture dish Medium (37°C), under an inverted microscope (100-200 times magnification), carefully search for sperm in the frozen carrier, use the intrafollicular single sperm injection needle to grab the sperm and transfer them to the sperm culture medium of the sperm culture dish for subsequent sperm ICSI of immobilized and matured eggs.

The invention discloses application of maca and maca polysaccharide in treating testis spermatogenesis disorders, and particularly relates to the application of the maca and the maca polysaccharide intreating the spermatogenesis disorders including oligospermia, asthenozoospermia and azoospermia, especially azoospermia caused by medicine. According to the application, an azoospermia model of a busulfan-induced mouse is used for verifying the improvement effect of the maca and the maca polysaccharide on the busulfan-induced azoospermia mouse.

The invention provides a biomarker for diagnosing asthenozoospermia, which belongs to the technical field of biomedicine and molecular diagnosis. The biomarker is TDRG1, and the Uniprot sequence number is Q3Y452. The expression level of TDRG1 is significantly down-regulated in spermatozoa of asthenozoospermia, and can be applied to the preparation of medicines capable of diagnosing infertility caused by asthenospermia.

The invention discloses an application of a compound in treating asthenozoospermia, which is an application of a compound shown as a structural formula I or pharmaceutically acceptable salt thereof inpreparation of a medicine or a medicine box for promoting sperm motility, prolonging sperm motility time and / or prolonging survival time of unfrozen sperms, and also discloses an application of the compound in preparation of the medicine or the medicine box for assisting reproduction, or in preparation of the medicine or the medicine box for treating asthenozoospermia.